LGI3 Antibody

LGI3 Antibody: The leucine-rich, glioma inactivated gene 3 (LGI3) is a member of the LGI family in which LGI1 is the exemplar. The LGI family consists of four of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Despite its high homology with LGI1 and similar pattern of expression, mutations in LGI3 have not been found to be associated with ADTLE. LGI3 expression is induced in rat astrocyte cultures by the amyloid beta (Abeta) peptide and accumulated on neuronal plasma membranes of aged monkey brains and co-localized with Abeta.

LGI3 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Two isoforms of LGI3 are known to exist; this LGI3 antibody will recognize both. This LGI3 antibody is predicted to be specific to LGI3 and not recognize other LGI proteins. The observed higher molecular weight band may represent a post-translationally modified form of LGI3.

Gu W, Gibert Y, Wirth T, et al. Using gene-history and expression analysis to assess the involvement of LGI genes in human disorders. Mol. Biol. Evol.2005; 22:2209-16.

Chernova OB, Somerville RP and Cowell JK. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene1998; 17:2873-81.